| Literature DB >> 30838411 |
Andreas Perrar1, Nico Dissmeyer2,3, Pitter F Huesgen1,4.
Abstract
Dynamic regulation of protein function and abundance plays an important role in virtually every aspect of plant life. Diversifying mechanisms at the RNA and protein level result in many protein molecules with distinct sequence and modification, termed proteoforms, arising from a single gene. Distinct protein termini define proteoforms arising from translation of alternative transcripts, use of alternative translation initiation sites, and different co- and post-translational modifications of the protein termini. Also site-specific proteolytic processing by endo- and exoproteases generates truncated proteoforms, defined by distinct protease-generated neo-N- and neo-C-termini, that may exhibit altered activity, function, and localization compared with their precursor proteins. In eukaryotes, the N-degron pathway targets cytosolic proteins, exposing destabilizing N-terminal amino acids and/or destabilizing N-terminal modifications for proteasomal degradation. This enables rapid and selective removal not only of unfolded proteins, but also of substrate proteoforms generated by proteolytic processing or changes in N-terminal modifications. Here we summarize current protocols enabling proteome-wide analysis of protein termini, which have provided important new insights into N-terminal modifications and protein stability determinants, protein maturation pathways, and protease-substrate relationships in plants.Entities:
Keywords: Acetylation; N-terminal modifications; arginylation; degradomics; positional proteomics; proteoform; proteolysis; proteostasis; termini enrichment
Mesh:
Substances:
Year: 2019 PMID: 30838411 PMCID: PMC6460961 DOI: 10.1093/jxb/erz104
Source DB: PubMed Journal: J Exp Bot ISSN: 0022-0957 Impact factor: 6.992
Fig. 1.Possible origins of diverse proteoforms derived from one gene. A multitude of mechanisms can influence the appearance of a specific proteoform at the transcriptional (top panel), translational (middle panel), and co-/post-translational level (bottom panel). Profiling N-termini and C-termini enables the differentiation of these various proteoforms. Alternative translation initiation (AUG.1 and AUG.2) will lead to an alternative N-terminus (N1.1 and N1.2), as does N-terminal methionine excision (NME). Further, NME allows for subsequent N-terminal modifications, such as N-terminal acetylation (orange) or N-terminal myristoylation (purple), increasing the number of proteoforms and their specific N-termini. Proteolytic processing, either endo- or exoproteolytic, represents an additional important mechanism for the introduction of new proteoforms on the post-translational level which can be assessed by either N- or C-termini profiling. Numbering of N- and C-termini corresponds to exon number from which the specific proteoform has derived. Subnumbering represents alternative N- or C-termini originating from the same exon.
Fig. 2.Basic workflow for the enrichment of protein N-terminal peptides by positive or negative selection. Proteolytic processing creates a new N-terminus (Nt) and a new C-terminus (Ct), also termed neo-termini (given in red). In positive selection strategies, neo-N-termini are selectively tagged with an affinity tag (blue oval) while for negative selection (bright green) the neo-N-termini are blocked by dimethylation (red triangle) prior to digestion. After digestion, positive selection strategies utilize an affinity capture of the added tag. Undesired digestion-generated peptides, as well as naturally blocked N-terminal peptides (e.g. acetylated N-termini, orange) and C-terminal peptides are washed out. The captured N-terminal peptides are subsequently released from the affinity column. Negative selection strategies modify all unblocked N-termini, exposing primary amines before digest. Undesired digestion-generated peptides are then tagged and/or captured for depletion. The desired neo-N-terminal peptides and naturally blocked N-terminal peptides are collected in the flow through.
Protocols for enrichment of N- or C-termini by positive selection
| Name | Target peptides and enrichment principle | Specific requirements | Starting material | Advantages and disadvantages | References |
|---|---|---|---|---|---|
|
| Unblocked and protease-generated neo-N-termini; tagging by enzymatic biotinylation | Subtiligase, TEV protease, biotinylated peptide esters | 30–300 mg | + Direct enrichment of neo-N-termini |
|
|
| Unblocked and protease-generated neo-C-termini; tagging by enzymatic biotinylation | Carboxypeptidase Y, biotinylated peptide ester | 200–300 µg per condition | + Direct enrichment of |
|
|
| Unblocked and protease-generated neo-N-termini; tagging by chemical biotinylation | NHS-SS-biotin, neutravidin resin | 1–10 mg | + Selective tagging of |
|
|
| Unblocked and protease-generated neo-C-termini; biotinylation using oxazolone chemistry | Synthetic Arg-NHNH-biotin-peptide | 10 µg per condition | + Selective tagging of neo-N- |
|
|
| Unblocked and protease-generated neo-N-termini; tagging by chemical biotinylation | NHS-SS-biotin, neutravidin resin | 2 mg | + Selective tagging of neo N-termini | G. |
Starting material refers to the amount of extracted and purified protein/proteome.
References in italics are step-by-step protocols.
Protocols for enrichment of N- or C-termini by negative selection
| Name | Target peptides and enrichment principle | Specific requirements | Starting material | Advantages and disadvantages | References |
|---|---|---|---|---|---|
|
| Modified and neo-N- and C-termini; enrichment by diagonal reverse phase chromatography | Capillary HPLC system with fraction collector | 1–3 mg | + proven in multiple publications |
|
|
| Modified and neo-N-termini; enrichment by diagonal SCX chromatography | Capillary HPLC system with fraction collector | 50–200 µg | + proven in multiple publications |
|
|
| Modified and neo-N-termini; enrichment by tip-based diagonal SCX chromatography | SCX beads | 4.3 µg per condition | + lowest amount of starting |
|
|
| Modified and neo-N-termini; other peptides removed by covalent binding to polymer and ultrafiltration | HPG-ALD polymer, size exclusion filter | 0.1–1 mg per condition | + robustness proven by independent application in multiple laboratories |
|
|
| Modified and neo-C-termini, other peptides removed with polymer and ultrafiltration | PAA polymer, labeling reagents, size exclusion filter | 1.5–2 mg per condition | – labor- and loss-intensive |
|
|
| Modified and neo-N-termini, other peptides removed by covalent binding to NHS-activated Sepharose | NHS-biotin, streptavidin column, amine-scavenging beads | 50 µg | + simple procedure using |
|
|
| Modified and neo-N-termini, other peptides removed with NHS-activated Sepharose | NHS-activated Sepharose | 50 µg | + simple procedure using |
|
|
| Modified and neo-N-termini, other peptides removed with NHS-activated Sepharose and ultrafiltration | NHS-activated Sepharose beads | 5 mg per condition | + simple procedure |
|
|
| Modified and neo-N-termini, other peptides removed by disulfonate modification + SCX chromatography | SCX-packed tips or HPLC system with SCX columns and fraction collector | 1.5–3 mg per condition | + flexible format allows |
|
|
| Modified and neo-N-termini, other peptides removed by hydrophobic tagging C18 trap depletion | C18 trap columns | 100 µg per condition | + well-established chemicals |
|
|
| Modified and neo-N-termini, other peptides removed by addition of phosphotag and TiO2 depletion | TiO2 affinity columns or beads | 100 µg per condition | + Chemistry used for depletion |
|
|
| Modified and neo-C-termini, other peptides removed by addition of phosphotag and TiO2 depletion | TiO2 affinity columns or beads | 200 µg per condition | + TiO2 chemistry used for |
|
|
| Modified and neo-N-termini, other peptides removed by sulfhydryl coupling to gold particles | Custom-made gold-covered graphene particles | 10 µg per sample | + low starting material |
|
Starting material refers to amount of extracted and purified protein/proteome
References printed in italics are step-by-step protocols, and those in bold list applications in plants.
Fig. 3.Enrichment and detection via N-terminally specific antibodies. Antibodies produced against N-terminal modifications can be used for enrichment and/or detection of modified proteins in various protocols and assays. (A) Antibodies are raised against peptides mimicking the N-termini of the desired target proteins or, as in the case of the ‘pan-arginylation’ antibodies, a random, highly immunogenic sequence. (B) Antisera are derived from different, subsequent bleedings to acquire a range of differentially performing antibodies and select ideal reagents. The resulting antisera need to be purified against unspecific (C) and specific peptides (D) lacking or showing the N-terminal modification (arginylation/additional Arg residue at the N-terminus of the natural protein sequence, acetyl- or formyl-groups). (E) Positive selection of N-terminally modified proteins or peptides by capture with the specific antibodies and wash-out of non-target proteins/peptides, followed by elution for identification by MS (F). The same antibodies can be utilized in immunological assays such as western blots (G) or immunocytochemistry (not shown). Red, unspecific antibody populations; green, specific antibody populations; R, Arg; AcM, acetylated Met; fM, formylated Met; C, Cys included at the C-terminus of antigenic peptide to increase antigenicity.
Antibodies raised against N-terminal arginylated sequences used for enrichment or immunological detection.
| Target | Use | Application | Sequence | Reference |
|---|---|---|---|---|
| Generic | Enrichment | Mass spectrometry, IP-MS | (R)D/EHKHANQHMSVC |
|
| Generic | Enrichment | Mass spectrometry, IP-MS | (R)DHKH |
|
| Generic | Enrichment | Mass spectrometry, IP-MS | (R)D/EHKHANQHMSVC |
|
| Arg-CRT | Detection | Western blot, immunocytochemistry | (R)DPAIYFK |
|
| Arg-BRCA1 | Detection | Western blot | (R)DVEIQGHTSFC |
|
| Arg-β actin | Detection | Dot blot (verification), western blot | (R)DDIAAL |
|
| Arg-BiP (ER chaperone BiP, also known as GRP78 and HSPA5, heat shock 70 kDa protein 5) | Detection | Dot blot (verification), western blot, immunocytochemistry | (R) EEEDKKEDVGC |
|
| Arg-CRT | Detection | Western blot | (R)EPAVYFKEQ |
|
| Arg-PDI | Detection | Western blot | (R)DAPEEEDHVL |
|
| Arg-CDC6 | Detection | Western blot | (R)DEPTFKASPPK |
|
| Arg-BRCA1 | Detection | Western blot | (R)DGEIKEDTSFA |
|
Antibodies raised against N-terminally acetylated or formylated sequences used for immunological detection
| Target | Use | Application | Sequence | Reference |
|---|---|---|---|---|
| MATα2 | Detection | Dot blot (verification), western blot | Ac-MNKIPIKDLLNC |
|
| Cog1 | Detection | Dot blot (verification), western blot | Ac-MDEVLPLFRDS |
|
| Generic (MD-D2-eK-ha) | Detection | Dot blot (verification), western blot | f-MDIAIGTYQEK |
|
Fig. 4.Characterization of cellular processes in plants by N-terminome profiling. N-terminome profiling has been applied to elucidate diverse cellular processes in plants. (A) N-termini as protein stability determinants in the N-end rule pathway for targeted degradation by the 26S proteasome. (B) The stromal terminome and maturation of nucleus-encoded plastidial proteins by the stromal processing peptidase (SSP) and potential additional proteases. (C) The alternative initiation of translation within the same mRNA resulting in two different proteoforms. (D) N-terminal protein modifications such as co-translational N-terminal initiator Met excision (NME) and Nα acetylation (NAA). (E) Identification of METACASPASE9 (MC9) protease substrates. (F) Proteolytic maturation of nucleus-encoded mitochondrial proteins after their import by the proteases ICP55 and OCT1. Ub, ubiquitin; E2/E3, E2/E3 ubiquitin ligases; TP, transit peptide; M, methionine; Ac, acetyl group.